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Abstract
Introduction Breast cancer risk may be determined by various
genetic, metabolic, and lifestyle factors that alter sex hormone
metabolism. Cytochrome P450 1A2 (CYP1A2) is responsible
for the metabolism of estrogens and many exogenous
compounds, including caffeine.
Methods In a cross-sectional study of 146 premenopausal and
149 postmenopausal women, we examined the relationships
between CYP1A2 activity and known or suspected risk factors
for breast cancer. Blood levels of sex hormones, lipids, and
growth factors were measured. In vivo CYP1A2 activity was
assessed by measuring caffeine metabolites in urine. Stepwise
and maximum R regression analyses were used to identify
covariates related to CYP1A2 activity after adjustment for
ethnicity.
Results In both menopausal groups CYP1A2 activity was
positively related to smoking and levels of sex hormone binding
globulin. In premenopausal women, CYP1A2 activity was also
positively related to insulin levels, caffeine intake, age, and
plasma triglyceride levels, and negatively related with total
cholesterol levels and body mass index. In postmenopausal
women CYP1A2 activity was positively associated with insulin-
like growth factor-1, and negatively associated with plasma
triglyceride, high-density lipoprotein cholesterol, and age at
menarche.
Conclusion These results suggest that CYP1A2 activity is
correlated with hormones, blood lipids, and lifestyle factors
associated with breast cancer risk, although some of the
observed associations were contrary to hypothesized directions
and suggest that increased CYP1A2 function may be
associated with increased risk for breast cancer.
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Introduction
Epidemiologic evidence suggests that endocrine factors
alter breast cancer risk. In both premenopausal and post-
menopausal women cancer risk is associated with events
that alter hormonal balance, such as age at menarche, par-
ity, body weight, body fat distribution, and use of exoge-
nous hormones. Prospective data from postmenopausal
women have also shown that modest increases (+15%) in
circulating sex hormone levels are associated with
increased future risk for developing breast cancer [1].
Exposure to sex hormones may be affected by various
genetic, metabolic, and lifestyle factors that can alter the
biosynthesis and metabolism of sex hormones. Function of
the cytochrome P450 1A2 (CYP1A2) enzyme might play a
role in determining estrogen exposure because it is princi-
pally responsible for the metabolism of 17β-estradiol after
initial conversion to estrone. CYP1A2 is a major phase I
enzyme, and accounts for about 15% of total liver P450
content [2]. The enzyme is most active in catalyzing 2-
hydroxylations [3], and in humans between 40% and 50%
AAMU = 5-acetylamino-6-amino-3-methyluracil; AFMU = 5-acetylamino-6-formylamino-3-methyluracil; BMI = body mass index; CMR = caffeine met-
abolic ratio; CYP1A2 = cytochrome P450 1A2; GH = growth hormone; HDL = high-density lipoprotein; IGF = insulin-like growth factor; IGFBP = 
insulin-like growth factor binding protein; LDL = low-density lipoprotein; SHBG = sex hormone binding globulin; 1U = 1-methylurate; 1, 3U = 1, 3-
dimethylurate; 1, 7U = 1, 7-dimethylurate; 1X = 1-methylxanthine; WHR = waist–hip ratio.Breast Cancer Research    Vol 6 No 4    Hong et al.
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of estrogens are hydroxylated at the C-2 position [4].
Increased formation of 2-hydroxylated estrogens would be
consistent with a reduced risk for breast cancer under a
'receptor-mediated' hypothesis because 2-hydroxyestro-
gens can bind only weakly to the estrogen receptor [5].
Higher CYP1A2 activity is therefore postulated to be asso-
ciated with reduced risk for breast cancer.
Previous research has shown that CYP1A2 activity can be
influenced by a number of factors including use of exoge-
nous hormones, body size, tobacco smoke., and intake of
coffee and cruciferous vegetables [6-8]. The rate of estro-
gen 2-hydroxylation can also be influenced by dietary fac-
tors [9]. The goal of the present study, conducted in a
cross-sectional sample of 295 women, was to identify the
determinants and covariates of CYP1A2 activity, particu-
larly those related to breast cancer risk. These include
potential associations with reproductive events, sex hor-
mone levels, the growth hormone (GH)/insulin-like growth
factor (IGF)-1 axis, body size, plasma lipids, smoking sta-
tus, and diet.
In vivo CYP1A2 function was examined by assessing caf-
feine clearance. Caffeine is a good probe for CYP1A2
function because 90% of caffeine clearance is mediated by
CYP1A2 [10]. Urinary caffeine metabolites have been used
to calculate a number of ratios that indicate CYP1A2 func-
tion. We chose to use the caffeine metabolic ratio (CMR),
which is calculated as follows: CMR = (5-acetylamino-6-
formylamino-3-methyluracil [AFMU] + 1-methylurate [1U] +
1 methylxanthine [1X])/1, 7-dimethylurate (1,7U). This is
because this parameter is not dependent on renal flow [11]
and is based only on metabolic end products of caffeine
metabolism, thus making the amount and timing of urine
collection relatively unimportant [10]. Measurement of the
CMR in 24-hour urine samples has been shown to be a via-
ble method of assessing CYP1A2 intake in populations
with widespread caffeine use [12]. In the present study
93% of women consumed sufficient levels of caffeine to
estimate CMR. Because daily caffeine intake is relatively
constant, urinary recovery of caffeine metabolites over a
24-hour period reflects CMRs observed with standardized
dosing [12].
Methods
The methods employed in the present study are published
in detail elsewhere [13] and are only briefly described here.
Ethical approval for the study protocol was given by the
Human Subjects Review Committee at the University of
Toronto, Canada.
Source of study subjects
Between 1994 and 1997, potential participants were iden-
tified from the mammographic units of Mount Sinai,
Women's College, and St. Michael's Hospital in Toronto.
The extent of mammographic density for all patients was
visually estimated by a radiologist and expressed as a per-
centage of breast area on a five-point scale. The purpose of
our approach to recruitment was to assemble a group of
women without breast cancer and with a wide range of
density levels by recruiting approximately equal numbers of
women in each of five categories of density, with over-rep-
resentation of the extreme categories. The number of
patients recruited into each of the five categories of radio-
logical density were as follows: <10%, n = 101; 10% to
<25%, n = 62; 25% to <50%, n = 60; 50% to <75%, n =
60; and = 75%, n = 99.
Recruitment
Potential participants were sent a letter and subsequently
telephoned about the study. Premenopausal women were
eligible if they were menstruating regularly, not pregnant or
breast-feeding, and had not had a hysterectomy or
oophorectomy. Postmenopausal women were eligible if
they had had spontaneous amenorrhea for at least 12
months, or had had a hysterectomy and were 50 years of
age or older, or had had a bilateral oophorectomy at any
age. A woman was excluded if she was taking any type of
exogenous hormone preparation, had breast augmentation
or reduction or a personal history of breast cancer, or was
being investigated for breast cancer. In total, 382 women
agreed to participate in the study, representing 88% of
those who were contacted and found to be eligible.
Measurements
Data and blood samples were collected after a 12-hour
overnight fast, and during the luteal phase of the menstrual
cycle (days 20–24) for premenopausal women. The mam-
mogram closest to the time of the blood draw was used
(mean difference 32 weeks).
Obtaining consent
Because examination of CYP1A2 activity was not a goal of
the original study, patients were subsequently mailed a let-
ter describing the goals of this component of the study, and
written consent was obtained to measure CYP1A2 activity.
Information on ethnicity was also obtained at this time. Of
382 eligible patients (193 premenopausal and 189 post-
menopausal women), 357 (93%) gave consent. Eight
women could not be contacted because they had moved
and could not be traced through either telephone directo-
ries or their physicians. Sixteen women were nonrespond-
ers after a minimum of four telephone reminders, and one
did not provide consent.
Ethnicity
By questionnaire (see below), each patient was asked their
country of birth, as well as the countries of birth for each of
their parents and grandparents. They were also asked the
question, 'What is your ethnic or cultural background?' andAvailable online http://breast-cancer-research.com/content/6/4/R352
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given instructions to mark all appropriate categories. Sub-
jects were classified as follows: black; white (e.g. British,
French, European, Latin/South American of European
background); native/aboriginal people of North America
(North American Indian, Inuit, Métis); East Asian (e.g. Chi-
nese, Japanese, Korean, Vietnamese); South Asian (e.g.
Indian from India, Pakistani, Punjabi, Tamil); other, with
specification; and 'don't know'. Because of low numbers in
groups other than Caucasians, the categories were col-
lapsed and described as Caucasian (white), East Asians,
Jewish, and other.
Epidemiologic and anthropometric data
Information about epidemiologic risk factors for breast den-
sity and breast cancer was collected by questionnaire, and
dietary information was obtained using a list-based food
frequency questionnaire developed by Block and cowork-
ers [14]. Each woman was weighed and measured for
height, and waist and hip circumference.
CYP1A2 activity
Caffeine (1, 3, 7-trimethylxanthine) is metabolized by
CYP1A2 and has been used to evaluate CYP1A2 activity
in vivo [15]. The best urinary metabolic ratio appears to be
(AFMU + 1X + 1U)/1,7U (i.e. the CMR) [16].
Urinary caffeine metabolites were measured by high-per-
formance liquid chromatography as previously described
[15], except for a modification of the composition of the
mobile phase. The mobile phase was composed of 1.3%
isopropanol, 0.2% isonitrile, and 0.1% phosphoric acid.
The caffeine metabolites were eluted at 1 ml/min and
detected by ultraviolet absorbance (0.05) at 280 nm. The
retention times of 1U, 1X and 1,7U and the internal stand-
ard (N-acetyl-p-aminophenol) were 9.9, 11.9, 29.8, and
14.2 min, respectively.
Urinary AFMU was first deformylated to stable 5-
acetylamino-6-amino-3-methyluracil (AAMU) and then
measured using the high-performance liquid chromatogra-
phy method reported by Tang and coworkers [15]. The
mobile phase consisted of 0.075% acetic acid and
0.075% phosphoric acid. AAMU and the internal standard
(hydrobenzyl alcohol) were eluted at a flow of 0.9 ml/min
and monitored by ultraviolet absorbance (0.04) at 263 nm.
The retention times of AAMU and the internal standard
were 13 and 36 min, respectively.
A standard urine sample with known caffeine metabolite
concentrations was analyzed across all days of sample
analyses with an interassay coefficient of variation of 9%.
Accuracy of the CYP1A2 measurement did not vary with
caffeine intake. After adjustment for smoking status, age,
body mass index (BMI), waist–hip ratio (WHR), and ethnic-
ity, coefficient of variations associated with mean CYP1A2
function across quartiles of caffeine intake were 56.8%,
55.3%, 57.0%, and 46.9% for premenopausal women, and
39.8%, 44.1%, 43.5%, and 42.4% for postmenopausal
women. Kashuba and coworkers [17] investigated the
intraindividual variability in CYP1A2 activity over a 3-month
period and the median coefficient of variation was 16.8%
(range 4.5–49.3%).
Caffeine intake
Dietary caffeine intake was assessed by summing the molar
concentrations of AAMU, 1, 7U, 1U, and 1, 3-dimethylurate
(1,3U) in urine and multiplying them by the 24-hour urine
volume to obtain total amount of caffeine metabolites
excreted in moles. This amount was multiplied by the
molecular weight of caffeine (194.19 g/mol) and divided by
1000 to obtain caffeine intake in milligrams. A correction
factor of 1.49 (1/0.67) was applied because the above
metabolites, on average, account for 67% of all excreted
caffeine metabolites [18].
Measurement of blood samples
Serum estradiol in premenopausal women and sex hor-
mone binding globulin (SHBG) levels were measured at
the London Regional Cancer Center in Ontario, Canada in
the laboratory of Geoffrey Hammond [19]. Percentage free
estradiol was estimated from a nomogram describing the
relationship between serum SHBG levels and percentages
of free estradiol in a reference population of premenopau-
sal and postmenopausal women of normal weight [20].
These values were used to calculate the free estradiol con-
centrations from the total estradiol measurements. Serum
estradiol levels in postmenopausal women, and IGF-1, IGF
binding protein (IGFBP)-3, and GH levels were measured
by Esoterix Center for Clinical Trials (Calabasas Hills, CA,
USA) [13]. Insulin and progesterone levels were measured
by the Clinical Biochemistry Laboratory at the Wellesley
Hospital in Toronto, Canada. Measurements of lipids and
lipoproteins were performed at the J Alick Little Lipid
Research Laboratory (St. Michael's Hospital, Toronto),
using the standardized Lipid Research Clinic method [21].
For hormone measurements, the percentage coefficient of
variation within hormone assays was less than 7% for all
(except for progesterone, which was 8.7%), and between
assays it was less than 10% for all (except progesterone,
which was 11.9%). The interassay coefficient of variation
was less than 4% for total cholesterol, triglycerides, and
high-density lipoprotein (HDL)-cholesterol.
Statistical methods
Data were analyzed using the SAS statistical software
package (version 6.12; SAS Institute Inc., Cary, NC, USA)
[22]. Data were inspected for normality and, when neces-
sary, transformed to approximate a normal distribution.
Details of the transformations used are given in the foot-
notes of tables. Differences in results were found forBreast Cancer Research    Vol 6 No 4    Hong et al.
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premenopausal and postmenopausal women; thus, all data
are presented stratified by menopausal status.
Relationships between CYP1A2 activity and hormone lev-
els, anthropometric measurements, blood lipids, and diet
were explored using multiple regression analysis. Ethnicity,
age, body size (BMI and WHR), and smoking status as
determinants of CYP1A2 activity [7] were included in all
models as potential confounders. Further adjustments
were made to control for potential confounding variables,
and details are given in the tables and figures. Because the
data analysis was exploratory in nature, the goal of the
study was to provide results for all relationships that might
potentially be associated with CYP1A2 activity. Subse-
quent research will be needed to confirm any relationships
identified here. Differences were thus considered signifi-
Table 1
Selected characteristics of study subjects by ethnicity: premenopausal women
With CYP1A2 results No CYP1A2 results5 
(n = 36)
Caucasian1 (n = 125) East Asian2 (n = 4) Jewish3 (n = 10) Other4 (n = 7)
Risk factors
Age (years) 44.8 (4.8) 46.8 (4.5) 45.4 (3.1) 44.7 (5.1) 45.1 (4.4)
Weight (kg) 68.1 (16.6) 54.8 (3.1) 59.4 (10.7) 64.9 (17.9) 69.1 (13.3)
BMI (kg/m2) 25.3 (6.1) 23.2 (0.9) 22.6 (3.5) 25.9 (6.5) 25.8 (5.1)
WHR 0.75 (0.06) 0.75 (0.04) 0.73 (0.07) 0.77 (0.05) 0.74 (0.06)
Age at menarche 
(years)
12.8 (1.5) 11.5 (1.3) 12.2 (0.6) 13.7 (1.6) 12.6 (1.5)
Age at first birth 
(years)
27.8 (5.7) 29.5 (0.7) 29.5 (2.7) 25.6 (9.7) 29.0 (6.4)
Number of live 
births
1.4 (1.2) 1.0 (1.2) 2.1 (1.3) 1.6 (1.3) 1.5 (1.2)
Mammographic 
density (%)6
27.4 (23.2) 47.6 (17.0) 40.2 (22.7) 25.9 (20.0) 28.4 (20.5)
CYP1A2 activity 
(CMR)7
6.3 (3.0) 6.5 (1.0) 5.0 (1.0) 6.1 (3.5) -
Hormones
Estradiol (pmol/l) 326.2 (217.0) 188.0 (127.6) 241.6 (173.3) 337.9 (188.4) 295.9 (221.5)
Free estradiol (%) 2.1 (0.7) 1.7 (0.5) 1.8 (0.7) 2.3 (0.7) 2.3 (0.5)
SHBG (nmol/l) 57.3 (27.1) 70.8 (17.2) 69.1 (26.6) 48.4 (24.6) 48.3 (19.0)
IGF-1 (ng/ml) 158.5 (35.6) 154.5 (36.2) 139.7 (36.6) 144.4 (24.8) 143.4 (34.0)
IGFBP-3 (mg/l) 2.7 (0.5) 2.6 (0.4) 2.7 (0.6) 2.7 (0.4) 2.6 (0.5)
Insulin (pmol/l) 74.0 (43.6) 47.4 (20.2) 53.8 (33.6) 86.0 (40.8) 77.0 (36.8)
Nutritional variables
Caffeine intake 
(mg/day)
161.0 (100.8) 138.8 (90.9) 132.0 (109.1) 212.9 (148.6) 58.0 (58.8)
Total energy intake 
(kcal/day)
1707.9 (467.1) 1640.0 (624.9) 1568.2 (346.4) 1995.4 (877.1) 1749.3 (485.2)
Blood lipids
Total cholesterol 
(mmol/l)
4.7 (0.9) 4.8 (0.4) 4.8 (0.8) 5.1 (0.9) 5.0 (1.0)
Triglycerides (mmol/l) 1.3 (0.9) 1.1 (0.1) 1.1 (0.5) 1.0 (0.6) 1.5 (1.1)
Values are expressed as mean (standard deviation). 1n = 86 for age at first birth; n = 124 for free estradiol, insulin-like growth factor (IGF-1), and 
IGF binding protein (IGFBP)-3; n = 121 for caffeine intake; and n = 123 for total energy intake. 2n = 2 for age at first birth. 3n = 8 for age at first 
birth. 4n = 5 for age at first birth. 5n = 25 for age at first birth and n = 7 for caffeine. 6Proportion of breast area occupied by dense tissue. 
7Estimated by caffeine metabolic ratio (CMR; see text for details). BMI, body mass index; WHR, waist–hip ratio.Available online http://breast-cancer-research.com/content/6/4/R352
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cant at P ≤ 0.05, but for descriptive purposes quartile least
square means were determined for variables associated
with CYP1A2 activity at P ≤ 0.20, and tests for trends were
performed as an additional method of assessing the data
for these variables. Although these results are based on
analyses of transformed data, they are presented in their
original units with 95% confidence intervals.
Table 2
Selected characteristics of study subjects by ethnicity: postmenopausal women
With CYP1A2 results No CYP1A2 results5 
(n = 26)
Caucasian1 (n = 126) East Asian2 (n = 6) Jewish3 (n = 5) Other4 (n = 12)
Risk factors
Age (years) 56.3 (4.6) 54.8 (3.8) 53.4 (2.5) 55.9 (4.2) 56.0 (4.5)
Weight (kg) 72.5 (16.6) 55.8 (9.8) 70.5 (18.1) 66.6 (15.7) 63.7 (17.0)
BMI (kg/m2) 26.8 (6.2) 23.2 (4.7) 25.9 (6.8) 25.6 (5.4) 23.3 (5.2)
WHR 0.77 (0.07) 0.77 (0.08) 0.80 (0.09) 0.80 (0.06) 0.75 (0.11)
Age at menarche 
(years)
13.1 (1.6) 13.0 (1.7) 12.6 (2.6) 13.0 (2.1) 12.8 (1.7)
Age at menopause 
(years)
49.1 (4.8) 50.8 (3.3) 49.1 (3.7) 48.8 (2.5) 48.2 (4.3)
Age at first birth 
(years)
26.0 (5.2) 34.6 (6.8) 22.8 (3.8) 31.0 (8.7) 25.4 (4.1)
Number of live 
births
1.8 (1.5) 1.8 (1.5) 2.2 (1.6) 1.0 (1.0) 1.3 (1.4)
Mammographic 
density (%)6
19.8 (18.5) 48.2 (8.9) 22.3 (24.6) 30.1 (23.8) 36.0 (22.1)
CYP1A2 activity 
(CMR)7
5.7 (2.2) 8.9 (1.8) 3.5 (1.7) 6.6 (2.8) -
Hormones
Estradiol (pmol/l) 44.6 (91.1) 31.8 (14.3) 27.9 (10.6) 51.1 (33.4) 72.6 (117.5)
Free estradiol (%) 2.6 (0.6) 2.4 (0.5) 2.4 (0.6) 2.7 (0.4) 2.2 (0.7)
SHBG (nmol/l) 41.0 (22.2) 47.8 (16.8) 47.6 (22.3) 36.9 (14.8) 54.2 (26.5)
IGF-1 (ng/ml) 127.8 (33.0) 126.7 (42.6) 137.0 (34.7) 137.3 (36.6) 139.3 (37.5)
IGFBP-3 (mg/l) 2.8 (0.5) 2.6 (0.4) 3.0 (0.5) 2.8 (0.4) 2.8 (0.6)
Insulin (pmol/l) 77.1 (46.4) 78.6 (46.7) 91.3 (40.1) 103.7 (53.9) 75.9 (52.9)
Nutritional variables
Caffeine intake 
(mg/day)
193.0 (117.3) 179.0 (147.6) 93.0 (59.4) 118.5 (73.2) 9.0 (9.7)
Total energy intake 
(kcal/day)
1779.7 (491.1) 1884.7 (646.4) 1234.3 (215.3) 1579.8 (274.3) 1648.0 (523.3)
Blood lipids
Total cholesterol 
(mmol/l)
5.6 (0.8) 5.7 (0.7) 5.4 (1.0) 5.6 (0.9) 5.2 (1.1)
Triglycerides 
(mmol/l)
1.5 (0.8) 1.4 (0.8) 1.8 (0.9) 1.4 (0.6) 1.2 (0.5)
Values are expressed as mean (standard deviation). 1n = 117 for age at menopause; n = 97 for age at first birth; n = 105 for total estradiol; and n 
= 125 for free estradiol, insulin-like growth factor (IGF-1), and IGF binding protein (IGFBP)-3. 2n = 5 for age at first birth, free estradiol, and sex 
hormone binding globulin (SHBG). 3n = 4 for age at first birth. 4n = 11 for menopausal age and total estradiol and n = 8 for age at first birth. 5n = 
23 for menopausal age, n = 14 for age at first birth, n = 22 for total estradiol, and n = 15 for caffeine. 6Proportion of breast area occupied by 
dense tissue. 7Estimated by caffeine metabolic ratio (CMR; see text for details). BMI, body mass index; WHR, waist–hip ratio.Breast Cancer Research    Vol 6 No 4    Hong et al.
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Table 3
CYP1A2 activity and risk factors for breast cancer: premenopausal women
Variable β (SE) F P Quartiles (mean CMR [95% confidence interval]) P for
trend
Q1 Q2 Q3 Q4
Age (years) 0.001 (0.007) 0.01 0.93
Age at first birth (years)2 0.16 (0.21) 0.56 0.46
Age at menarche (years) 0.03 (0.03) 1.80 0.18 6.11
(5.12–7.29)
6.55
(5.49–7.81)
7.39
(5.84–9.35)
6.62
(5.03–8.71)
0.16
BMI (kg/m2)2 -0.43 (0.19) 5.05 0.03 7.76
(6.32–9.53)
6.11
(5.09–7.33)
6.17
(5.02–7.57)
6.16
(4.89–7.76)
0.04
WHR 1.26 (0.70) 3.23 0.07 5.89
(4.80–7.24)
6.01
(4.90–7.37)
6.46
(5.31–7.86)
7.20
(5.87–8.83)
0.06
Caffeine (mg/day)1 0.020 (0.007) 6.32 0.01 5.42
(4.49–6.54)
6.37
(5.29–7.68)
6.28
(5.17–7.64)
6.94
(5.84–8.24)
0.02
Alcohol (kcal/day)2 0.03 (0.02) 2.13 0.15 5.17
(4.33–6.16)
5.17
(4.29–6.23)
5.88
(4.85–7.12)
6.12
(5.03–7.45)
0.05
Cholesterol (mg/day)2 0.09 (0.08) 1.29 0.26
Total energy (kcal/day)1 0.01 (0.01) 6.05 0.02 5.73
(4.70–6.98)
6.18
(5.00–7.64)
6.58
(5.46–7.93)
6.81
(5.56–8.33)
0.06
Carbohydrate (g/day)1 0.02 (0.02) 2.26 0.14 5.87
(4.84–7.13)
6.75
(5.51–8.26)
6.30
(5.13–7.74)
6.63
(5.45–8.07)
0.34
Fat intake (g/day)1 0.05 (0.02) 4.33 0.04 6.04
(5.20–7.01)
6.94
(5.98–8.05)
6.38
(5.46–7.45)
7.01
(6.03–8.15)
0.25
Protein intake (g/day)2 0.29 (0.11) 7.81 0.006 6.01
(4.97–7.27)
6.74
(5.45–8.33)
6.20
(5.08–7.55)
6.93
(5.65–8.50)
0.28
Total estradiol (pmol/l)3 -0.001 (0.006) 0.01 0.92
Free estradiol (%)2 -0.05 (0.01) 11.02 0.001 6.62
(5.51–7.96)
7.46
(6.16–9.04)
5.99
(4.90–7.31)
5.16
(4.19–6.35)
0.007
SHBG (nmol/l)4 0.07 (0.02) 10.89 0.001 5.13
(4.16–6.35)
6.09
(4.96–7.46)
7.57
(6.17–9.28)
6.73
(5.64–8.03)
0.004
Progesterone (nmol/l)1 -0.01 (0.02) 0.40 0.53
FSH (IU/l)2 0.01 (0.04) 0.01 0.91
GH (µg/l)5 0.01 (0.03) 0.14 0.71
IGF-1 (ng/ml)6 0.30 (0.22) 1.73 0.19 5.59
(4.59–6.81)
6.59
(5.38–8.06)
7.63
(6.19–9.41)
6.75
(5.41–8.43)
0.07
IGFBP-3 (mg/l)7 -0.14 (0.31) 0.20 0.66
Insulin (pmol/l)2 0.24 (0.09) 6.91 0.01 5.44
(4.51–6.57)
5.52
(4.49–6.78)
7.16
(5.91–8.68)
7.61
(6.19–9.37)
0.0009
Total cholesterol (mmol/l)2 -0.74 (0.20) 13.84 0.0003 7.37
(5.93–9.17)
6.88
(5.71–8.28)
6.24
(5.14–7.58)
5.64
(4.62–6.89)
0.006
LDL-cholesterol (mmol/l)2 -0.44 (0.15) 8.82 0.004 7.28
(5.91–8.96)
6.77
(5.60–8.19)
6.67
(5.54–8.04)
5.24
(4.30–6.39)
0.004
HDL-cholesterol (mmol/l)2 -0.27 (0.15) 3.35 0.07 7.05
(5.76–8.63)
6.17
(5.06–7.52)
6.83
(5.60–8.32)
5.83
(4.79–7.09)
0.11
Triglycerides (mmol/l)2 -0.02 (0.07) 0.04 0.83
A total of 146 premenopausal women were studied (n = 101 for age at first birth; n = 144 total estradiol, sex hormone binding globulin [SHBG], 
alcohol intake, dietary cholesterol, energy intake, carbohydrate intake, total fat intake, and protein intake; n = 145 for free estradiol; n = 143 for 
growth hormone [GH], insulin-like growth factor [IGF]-1, and IGF binding protein [IGFBP]-3; and n = 142 for caffeine intake). Cytochrome P450 
1A2 (CYP1A2) activity is log transformed and modeled as the dependent variable for all models. Models are adjusted for age, smoking status, 
body mass index (BMI), waist–hip ratio (WHR), and ethnicity. BMI models do not adjust for BMI and WHR models do not adjust for WHR. 
Quartile means (95% confidence interval) are provided for variables associated with CYP1A2 activity (P ≤ 0.20). 1Square root transformed. 2Log 
transformed. 3Square root transformed; models adjusted for SHBG. 4Square root transformed; models adjusted for total estradiol levels. 5Log 
transformed; analyses adjusted for IGF-1 and IGFBP-3. 6Square root transformed; analyses adjusted for growth hormone and IGFBP-3. 7Square 
root transformed; analyses adjusted for GH and IGF-1. CMR, caffeine metabolic ratio; FSH, follicle-stimulating hormone; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; SE, standard error.Available online http://breast-cancer-research.com/content/6/4/R352
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Table 4
CYP1A2 activity and risk factors for breast cancer: postmenopausal women
Variable β (SE) F P Quartiles (mean CMR [95% confidence interval]) P for
trend
Q1 Q2 Q3 Q4
Age (years) -0.012 (0.006) 4.51 0.04 7.17
(6.18–8.32)
6.42
(5.60–7.37)
6.69
(5.72–7.82)
5.93
(5.07–6.94)
0.02
Age at first birth (years)2 0.02 (0.15) 0.03 0.87
Age at menarche (years) -0.03 (0.02) 3.97 0.05 6.75
(5.91–7.72)
6.96
(5.90–8.20)
6.69
(5.60–7.98)
5.75
(4.92–6.73)
0.04
Age at menopause (years) -0.004 (0.006) 0.33 0.57
BMI (kg/m2)2 -0.45 (0.14) 0.10 0.75
WHR -0.96 (0.42) 5.19 0.02 6.69
(5.67–7.91)
6.83
(5.79–8.05)
6.39
(5.49–7.43)
6.04
(5.17–7.05)
0.17
Caffeine (mg/day)1 -0.003 (0.006) 0.23 0.64
Alcohol (kcal/day)2 -0.02 (0.02) 1.26 0.26
Cholesterol (mg/day)2 0.02 (0.06) 0.08 0.78
Total energy (kcal/day)1 0.003 (0.005) 0.42 0.52
Carbohydrate (g/day)1 0.01 (0.01) 0.32 0.57
Fat intake (g/day)1 0.02 (0.02) 1.03 0.31
Protein intake (g/day)2 0.04 (0.09) 0.20 0.66
Total estradiol (pmol/l)3 -0.26 (0.42) 0.40 0.53
Free estradiol (%)2 -0.03 (0.01) 5.11 0.03 7.04
(6.03–8.22)
7.07
(6.04–8.27)
5.86
(5.05–6.80)
5.96
(4.97–7.15)
0.01
SHBG (nmol/l)4 0.03 (0.02) 1.80 0.18 5.96
(4.98–7.14)
5.69
(4.88–6.63)
6.98
(5.91–8.24)
6.55
(5.55–7.72)
0.08
Progesterone, (nmol/l)2 -0.02 (0.05) 0.23 0.63
FSH (IU/l)2 0.06 (0.07) 0.60 0.44
GH (µg/l)5 0.02 (0.02) 0.57 0.45
IGF-1 (ng/ml)6 0.85 (0.33) 6.68 0.01 6.30
(5.30–7.48)
6.49
(5.50–7.65)
6.42
(5.43–7.60)
7.46
(6.27–8.89)
0.13
IGFBP-3 (mg/l)7 -0.66 (0.23) 8.32 0.005 8.04
(6.82–9.48)
6.27
(5.29–7.44)
6.40
(5.46–7.51)
6.01
(5.11–7.07)
0.003
Insulin (pmol/l)2 -0.01 (0.08) 0.01 0.92
Total cholesterol (mmol/l)2 -0.35 (0.18) 3.70 0.06 6.98
(5.97–8.16)
6.88
(5.90–8.04)
6.40
(5.46–7.51)
6.13
(5.28–7.11)
0.05
LDL-cholesterol (mmol/l)2 -0.13 (0.13) 1.00 0.32
HDL-cholesterol (mmol/l)2 -0.16 (0.12) 1.82 0.18 5.77
(5.02–6.63)
5.53
(4.83–6.34)
5.63
(4.89–6.48)
4.85
(4.17–5.66)
0.08
Triglycerides (mmol/l)2 -0.12 (0.06) 3.37 0.07 6.94
(5.90–8.16)
6.68
(5.75–7.75)
6.52
(5.52–7.70)
6.15
(5.24–7.20)
0.15
A total of 149 postmenopausal women were studied (n = 114 for age at first birth; n = 139 for age at menopause; n = 126 for total estradiol and 
sex hormone binding globulin [SHBG]; n = 147 for free estradiol; and n = 134 for growth hormone [GH], insulin-like growth factor [IGF]-1, and 
IGF binding protein [IGFBP]-3). Cytochrome P450 1A2 (CYP1A2) activity is log transformed and modeled as the dependent variable for all 
models. Models are adjusted for age, smoking status, body mass index (BMI), waist–hip ratio (WHR), and ethnicity. BMI models do not adjust for 
BMI and WHR models do not adjust for WHR. Quartile means (95% confidence interval) are provided for variables associated with CYP1A2 
activity (P ≤ 0.20). 1Square root transformed. 2Log transformed. 3Power transformation used, in which y = (1 - 1/sqrt [estradiol + 0.5]) × 2; 
models adjusted for SHBG. 4Square root transformed; models adjusted for total estradiol levels. 5Log transformed; analyses adjusted for IGF-1 
and IGFBP-3. 6Square root transformed; analyses adjusted for growth hormone and IGFBP-3. 7Square root transformed; analyses adjusted for 
GH and IGF-1. CMR, caffeine metabolic ratio; FSH, follicle-stimulating hormone; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SE, 
standard error.Breast Cancer Research    Vol 6 No 4    Hong et al.
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Stepwise and maximum R regression analyses were used
to identify covariates related to CYP1A2 activity after con-
trolling for potential confounders. If variables were highly
correlated (R ≥ 0.75), then the variable most strongly asso-
ciated with CYP1A2 activity (from the analyses presented
in Tables 3 and 4) was included in the model. In general,
variables correlated at less than 0.8 will not pose problems
in regression analysis [23]. Percentage free estradiol was
not included in the models as a potential covariate because
values were calculated from total serum estradiol and
SHBG levels [24]. Low-density lipoprotein (LDL)-choles-
terol levels were not included as a potential covariate
because of high correlations with total cholesterol level (R
> 0.84). Total energy intake was not included in the models
because of high correlations with protein, fat, and carbohy-
drate intake (R > 0.79). Variables identified from the step-
wise and maximum R regressions with P ≤ 0.15 were re-
analyzed with linear regression, and only variables that con-
tinued to be significant at the P ≤ 0.15 level were reported.
For descriptive purposes, each variable included in the final
model was also categorized, in turn, into quartiles so that
least square (adjusted) means for CYP1A2 activity could
be determined. P values for trend across quartiles of each
variable were determined.
Values for GH were missing in 19 (premenopausal, n = 3;
postmenopausal, n = 16) and GH was undetectable in 120
(premenopausal, n = 53; postmenopausal, n = 67) of 357
(34%) women in the study. A missing value occurred when
the volume of serum available for a participant was insuffi-
cient for both a GH and IGF-1 analysis; in such instances,
IGF-1 values were determined and GH assays were not
performed. Nondeterminate values were assumed to be
due to the episodic and pulsatile nature of GH release,
which results in considerable variability in basal hormone
levels. A value of 0.2 ng/l was assigned to the 120 unde-
tectable measurements and represents the lower limit of
sensitivity for the assay. To determine whether we were
introducing a bias into the results, we looked for a relation-
ship between GH detectability and CYP1A2 activity, and
found that none existed (P = 0.71).
Results
Participation rate
Of 357 (182 premenopausal and 175 postmenopausal)
women who consented to participate in the study, 40
(11.2%; 29 premenopausal and 11 postmenopausal) did
not have urine samples and 22 (6.2%; seven premenopau-
sal and 15 postmenopausal) had insufficient excretion of
caffeine metabolites for estimating CYP1A2 activity. This
left 146 postmenopausal women and 149 postmenopausal
women in whom CYP1A2 activity was measurable, repre-
senting 93% of those with urine samples and 83% of
eligible women. The overall participation rate for this por-
tion of the study was 77% (295/382).
Subject characteristics by ethnicity
Selected characteristics of the 146 premenopausal and
149 postmenopausal study participants with CYP1A2
phenotype data are shown according to ethnicity in Tables
1 and 2, respectively. Of the women studied, 85% were
Caucasian, 3.4% were East Asian, 5.1% were Jewish, and
6.4% were from other ethnic groups. The mean age was 45
years in premenopausal and 56 years in postmenopausal
women. The two groups were similar in age at menarche,
age at first birth, total number of live births, insulin levels,
and daily caffeine and total energy intake. Postmenopausal
women had higher average BMI and WHR, and lower cir-
culating levels of estradiol, SHBG and IGF-1, lower levels
of percentage mammographic density, and higher levels of
free estradiol, IGFBP-3, and total plasma cholesterol and
triglycerides.
Compared with Caucasians, premenopausal and postmen-
opausal East Asian women and premenopausal Jewish
women had lower mean BMIs, lower levels of total and free
estradiol, higher levels of SHBG, and greater percentage
breast density. Among premenopausal women, both East
Asians and Jewish women had lower levels of circulating
insulin than did Caucasians, and Jewish women also had
lower IGF-1 levels. In postmenopausal women, compared
with Caucasians, East Asians were older at age of first birth
and had higher levels of CYP1A2 activity, and Jewish
women had lower CYP1A2 activity, higher levels of SHBG,
IGF-1, and insulin, and lower levels of daily energy intake.
In premenopausal women, those without CYP1A2 data
had slightly lower SHBG and IGF-1 levels. In postmeno-
pausal women, those without CYP1A2 results weighed
less, and had lower BMIs and WHRs, and lower levels of
total blood cholesterol and triglycerides. Mammographic
density, estradiol, SHBG, and IGF-1 levels were also
higher in postmenopausal women without CYP1A2 results.
CYP1A2 activity
In premenopausal women the CMR ranged from 0.77 to
23.5, with a mean ± standard deviation of 6.21 ± 2.86 and
a median of 5.84. In postmenopausal women the ratio
ranged from 1.84 to 17.06 with a mean ± standard devia-
tion of 5.85 ± 2.32, and median of 5.40. This magnitude of
interindividual variation is similar to that in previous reports
showing up to a 30-fold variation in enzyme activity [25,26].
The population distribution of CMR in the present study
was log-normal, and similar to that in other studies using
the same urinary ratio [7,12,26].
When CYP1A2 activity was compared between different
ethnic groups (Tables 1 and 2), there was some indication,
based on small numbers, that Jewish women may have
lower CMRs than Caucasians (premenopausal 5.0 ± 1.0,
postmenopausal 3.5 ± 1.7). Postmenopausal East AsianAvailable online http://breast-cancer-research.com/content/6/4/R352
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women (n = 6) were observed to have a higher mean CMR
than Caucasian women (8.9 ± 1.8). This, however, was
likely to have occurred by chance due to low numbers
because previous studies generally showed CYP1A2 func-
tion to be lower [27] or not different [7] between Orientals
and Caucasians.
CYP1A2 activity and risk factors for breast cancer
Tables 3 and 4 show relationships between CYP1A2 activ-
ity and known or suspected risk factors for breast cancer.
Ethnicity, age, body size (BMI and WHR), and smoking sta-
tus as determinants of CYP1A2 activity [7] were included
in all models as potential confounders. For variables asso-
ciated with CYP1A2 activity at P ≤ 0.20, quartile least
square means were determined for descriptive purposes.
Age and reproductive variables
CYP1A2 activity was not related to menopausal status (P
= 0.51; data not shown) or to age at menopause in post-
menopausal women (P = 0.57). CYP1A2 activity was not
related to parity (P > 0.61; data not shown) or age at first
full-term pregnancy (P  > 0.46) in either menopausal
groups, but in postmenopausal women was negatively
associated with age (P = 0.04) and age at menarche (P =
0.05). Adjusted mean CYP1A2 activities were 17.3% and
14.8% lower for postmenopausal women in the fourth
quartile of age (P for trend = 0.02) and age at menarche (P
for trend = 0.04), respectively, compared with those in the
first quartile.
Body weight
BMI was inversely associated with CYP1A2 activity in pre-
menopausal (P = 0.03) but not in postmenopausal women
(P = 0.75). In premenopausal women, despite a significant
P value for trend (P for trend 0.04), mean CMR was higher
only for women in the lowest quartile of BMI (7.76) as com-
pared with the other quartiles (6.11–6.17). There was
some evidence that WHR was positively associated with
CYP1A2 activity in premenopausal women (P = 0.07), and
inversely related to CYP1A2 activity in postmenopausal
women (P = 0.02). Mean CMRs were respectively 22.2%
higher and 9.7% lower in premenopausal and postmenop-
uasal women for those in the highest quartile of WHR as
compared with those in the lowest quartile.
Lifestyle factors
Lifestyle factors examined were smoking and diet. Smoking
is known to induce CYP1A2 activity [7], and as expected
smokers had higher CYP1A2 activity than did nonsmokers.
Compared with nonsmokers, mean CMR was 55.6%
higher in premenopausal smokers and 54.3% higher in
postmenopausal smokers (data not shown).
Of the nutritional variables examined, caffeine (P = 0.01),
total energy intake (P = 0.02), fat intake (P = 0.04), and
protein intake (P = 0.006) were positively associated with
CYP1A2 activity in premenopausal women. Of these, only
caffeine (P for trend = 0.02) and total energy intake (P for
trend 0.06) exhibited significant or borderline significant
associations based on tests for trend across quartiles of
intake. Compared with women in the lowest quartiles, mean
CMRs were 21.2% and 18.8% higher, respectively, for
women in the highest quartile of caffeine and total energy
intake. In postmenopausal women, CYP1A2 activity did not
vary with caffeine intake or any of the other dietary compo-
nents tested.
Sex hormones
CYP1A2 activity was not associated with total estradiol (P
> 0.53), progesterone (P  > 0.53), or follicle-stimulating
hormone (P > 0.44) levels in either menopausal group.
CYP1A2 activity was, however, negatively associated with
percentage free estradiol in both premenopausal (P  =
0.001) and postmenopausal (P  = 0.03) women. Mean
CMRs were respectively 22% and 15% lower for premen-
opausal (P for trend = 0.007) and postmenopausal (P for
trend = 0.01) women in the highest quartile of circulating
estradiol levels compared with women in the lowest quar-
tile. A positive association with SHBG was observed for
premenopausal women (P = 0.001), in which women in the
highest quartile of SHBG levels had a 31.2% higher mean
CMR than did women in the lowest quartile (P for trend
0.004).
Insulin and growth hormone/insulin-like growth factor-1 axis
GH levels were not associated with CYP1A2 activity in
either menopausal groups (P = 0.45). For premenopausal
women, a positive relationship was observed between
endogenous insulin levels and CYP1A2 activity (P = 0.01).
Those in the highest quartile had a 39.9% higher mean
CMR than did those in the lowest quartile. The test for trend
was also significant (P = 0.0009). No other associations
were observed. In postmenopausal women, CYP1A2 activ-
ity was positively related to IGF-1 levels (P = 0.01), nega-
tively associated with its main binding protein IGFBP-3 (P
= 0.005), and not associated with endogenous insulin lev-
els (P = 0.92). Mean CMRs were only raised for women in
the highest quartile of IGF-1, at 7.5 (+15 to 19%), as com-
pared with mean CMRs of 6.3–6.5 in the first three quar-
tiles; the test for trend was not statistically significant (P =
0.13). Women in the highest quartile for IGFBP-3 had a
25.2% lower mean CMR than did those in the lowest
quartile.
Blood lipids
In premenopausal women, CYP1A2 activity was inversely
associated with total plasma cholesterol (P  = 0.0003),
LDL-cholesterol (P  = 0.004) and HDL-cholesterol (P  =
0.07) levels, but not with triglyceride levels (P = 0.83).
Tests for trends, however, were only significant for total (PBreast Cancer Research    Vol 6 No 4    Hong et al.
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= 0.006) and LDL (P = 0.004) cholesterol. Mean CMRs
were 23.5% and 28.0% lower for women in the highest
quartile of total cholesterol and LDL-cholesterol, respec-
tively, as compared with those in the lowest quartile. In con-
trast, no statistically significant relationships were detected
between CYP1A2 activity in postmenopausal women and
plasma LDL-cholesterol, although borderline negative rela-
tionships were observed for total cholesterol (P = 0.06)
and triglyceride levels (P = 0.07). Mean CMRs for women
in the highest quartile of total cholesterol (P for trend =
0.05) and blood triglyceride levels (P for trend = 0.15)
were 12.2% and 11.4% lower, respectively, than for
women in the lowest quartile.
Family history of breast cancer
Family history of breast cancer was not significantly related
to CYP1A2 activity in either premenopausal or postmeno-
pausal women (data not shown; P > 0.10).
Covariates of CYP1A2 activity
Stepwise and maximum R regression analyses were used
to identify covariates related to CYP1A2 activity after con-
trolling for any mutual confounding. All variables shown in
Tables 3 and 4, as well as smoking status, were included in
the models except those that were highly correlated (see
Statistical methods section, above, for details). Findings
are shown in Tables 5 and 6.
In both menopausal groups CYP1A2 activity was positively
related to smoking (P < 0.0001) and SHBG (P ≤ 0.004). In
premenopausal women CYP1A2 activity was also posi-
tively related to endogenous insulin levels (P  = 0.008),
caffeine intake (P = 0.007), age (P = 0.03) and plasma trig-
lyceride levels (P = 0.04), and negatively related to total
cholesterol levels (P = 0.0003) and BMI (P = 0.04). All
tests for trend across quartiles for each variable were sig-
nificant except for blood triglycerides (P for trend = 0.24).
In postmenopausal women, CYP1A2 activity was positively
associated with IGF-1 levels (P = 0.03), and negatively
associated with plasma triglyceride (P = 0.0001) and HDL-
cholesterol levels (P = 0.002), and age at menarche (P =
0.02). All tests for trend across quartiles of each variable
were significant except for IGF-1 (P for trend = 0.22). Of
the variance in CYP1A2 activity, 42% and 41% was
Table 5
Covariates of CYP1A2 activity based on maximum R and stepwise regression: premenopausal women
Variable β (SE) F P Quartiles (mean [95% confidence interval]) P for
trend
Model R2 = 0.42 Q1 Q2 Q3 Q4
Current smoker?
No (n = 121) 5.35 (4.76–6.03)1 19.48 <0.0001
Yes (n = 21) 7.69 (6.41–9.23)
SHBG2 0.07 (0.02) 14.21 0.0002 5.23
(4.39–6.22)
6.33
(5.34–7.50)
7.25
(6.11–8.60)
7.06
(6.08–8.21)
0.0004
Total cholesterol (mmol/
day)3
-0.77 (0.21) 14.02 0.0003 7.02
(5.75–8.58)
6.39
(5.42–7.54)
6.40
(5.42–7.55)
5.55
(4.66–6.60)
0.04
Insulin (pmol/l)3 0.21 (0.08) 7.24 0.008 5.66
(4.82–6.65)
5.69
(4.75–6.82)
6.63
(5.64–7.78)
7.61
(6.41–9.05)
0.001
Caffeine intake (mg/day)2 0.019 (0.007) 7.59 0.007 5.70
(4.82–6.75)
6.28
(5.31–7.42)
6.59
(5.51–7.87)
7.17
(6.15–8.35)
0.006
Age (years) 0.014 (0.006) 5.00 0.03 5.84
(4.93–6.93)
6.11
(5.11–7.30)
6.63
(5.71–7.70)
6.98
(5.84–8.34)
0.02
Triglycerides (mmol/day)3 0.14 (0.07) 4.18 0.04 6.12
(5.14–7.28)
6.27
(5.35–7.36)
6.34
(5.38–7.48)
7.13
(5.81–8.74)
0.24
BMI -0.37 (0.18) 4.51 0.04 7.65
(6.49–9.02)
6.25
(5.38–7.27)
5.91
(5.00–6.98)
6.53
(5.41–7.89)
0.01
HDL (mmol/day) -0.20 (0.14) 2.20 0.14 7.23
(6.11–8.56)
6.20
(5.29–7.27)
6.82
(5.80–8.03)
5.63
(4.77–6.65)
0.05
A total of 142 premenopausal women were studied. Model has been adjusted for ethnicity. Potential predictors of cytochrome P450 1A2 
(CYP1A2) activity included in the stepwise and maximum R regression models were: age, number of livebirths, age at menarche, smoking status, 
body mass index (BMI), waist–hip ratio (WHR), caffeine intake, alcohol intake, dietary cholesterol, total carbohydrate intake, total fat intake, protein 
intake, total blood cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, dehydroepiandrosterone sulphate (DHEAS), total estradiol, 
sex hormone binding globulin (SHBG), progesterone, follicle stimulating hormone (FSH), growth hormone, insulin-like growth factor (IGF)-1, and 
IGF binding protein (IGFBP)-3. 1Least square means (95% confidence interval) reported for smokers and nonsmokers. Quartile least square 
means (95% confidence interval) provided for variables associated with CYP1A2 activity (P ≤ 0.15). 2Square root transformed. 3Natural log 
transformed. SE, standard error.Available online http://breast-cancer-research.com/content/6/4/R352
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explained in premenopausal and postmenopausal women,
respectively.
Discussion
In the present study we found that CYP1A2 activity, as
measured by the CMR, varied 30-fold in premenopausal
women and ninefold in postmenopausal women, but as in
previous studies mean values did not vary with menopausal
status [6]. CYP1A2 activity was found in both menopausal
groups, through stepwise and maximum R regression, to be
independently associated with a number of covariates,
including smoking status, serum levels of SHBG, circulat-
ing levels of blood cholesterol, and triglycerides. CYP1A2
activity was also associated with age, BMI, endogenous
insulin levels, and caffeine intake in premenopausal women,
and with IGF-1 levels and age at menarche in postmeno-
pausal women. These results suggest that CYP1A2 activity
is associated with a number of risk factors associated with
breast cancer.
In both premenopausal and postmenopausal women,
approximately 40% of the variability associated with
CYP1A2 activity was explained by the lifestyle, hormonal,
and host factors examined in the study. The remaining 60%
of variability not explained by our models point to unexam-
ined factors, which may in part be genetic. In a twin study
of Caucasians conducted in Denmark [28], CYP1A2 activ-
ity was determined for 49 monozygotic twin pairs and 34
same-sex dizygotic twin pairs concordant for nonsmoking
and nonuse of oral contraceptives. A biometrical model for
the caffeine ratio including only additive genetic factors and
unique environmental factors was the best fitting model
and gave a heritability estimate of 0.725 (95% confidence
interval 0.577–0.822), suggesting that CYP1A2 activity is
mainly under genetic control. Several genetic polymor-
phisms have been identified to date in the CYP1A2 gene,
including one associated with greater inducibility [29] and
one associated with decreased inducibility [8]. The extent,
however, to which these polymorphisms explain the interin-
dividual variation associated with CYP1A2 activity is
unclear, particularly in nonsmokers [29]. Results from this
study add to the evidence that CYP1A2 function is related
to traits that are in part under genetic control, such as blood
levels of IGF-1 and body size [30,31].
In the present study, CYP1A2 function was positively
related to insulin levels in premenopausal women and
positively, but weakly, related to IGF-1 levels in postmeno-
pausal women. Because both insulin [32,33]. and IGF-1
[34] levels have been linked to increased risk for breast
cancer and/or recurrence, our findings suggest that
CYP1A2 function is associated with increased rather than
decreased breast cancer risk as hypothesized.
Given the cross-sectional nature of the study, it is unclear
whether CYP1A2 activity is affected by insulin and IGF-1
Table 6
Covariates of CYP1A2 activity based on maximum R and stepwise regression: postmenopausal women
Variable β (SE) F P Quartiles (mean [95% confidence interval]) P for
trend
Model R2 = 0.41 Q1 Q2 Q3 Q4
Current smoker?
No (n = 133) 5.05 (4.58, 5.57)1 24.52 <0.0001
Yes (n = 14) 7.69 (6.45–9.17)
Triglycerides (mmol/day)3 -0.28 (0.07) 15.49 0.0001 7.22
(6.15–8.42)
6.40
(5.53–7.42)
6.28
(5.34–7.39)
5.41
(4.59–6.38)
0.003
HDL (mmol/day)3 -0.42 (0.13) 10.57 0.001 7.39
(6.48–8.43)
6.49
(5.66–7.44)
6.62
(5.83–7.52)
5.58
(4.80–6.49)
0.008
SHBG2 0.05 (0.02) 8.49 0.004 5.95
(5.19–6.82)
6.30
(5.58–7.11)
7.39
(6.48–8.43)
7.03
(6.19–7.98)
0.01
Age at menarche (years) -0.03 (0.02) 5.17 0.02 6.73
(6.01–7.54)
7.08
(6.27–7.99)
6.69
(5.76–7.78)
5.60
(4.89–6.41)
0.03
IGF-1 (ng/ml)2 0.04 (0.02) 4.74 0.03 6.49
(5.71–7.39)
6.55
(5.77–7.44)
6.28
(5.59–7.05)
7.34
(6.40–8.41)
0.22
A total of 147 postmenopausal women were studied. Model has been adjusted for ethnicity. Potential predictors of cytochrome P450 1A2 
(CYP1A2) activity included in the stepwise and maximum R regression models were: age, number of livebirths, age at menarche, age at 
menopause, smoking status, body mass index (BMI), waist–hip ratio (WHR), caffeine intake, alcohol intake, dietary cholesterol, total carbohydrate 
intake, total fat intake, protein intake, total blood cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, dehydroepiandrosterone 
sulphate (DHEAS), total estradiol, sex hormone binding globulin (SHBG), progesterone, follicle stimulating hormone (FSH), growth hormone, 
insulin-like growth factor (IGF)-1, and IGF binding protein (IGFBP)-3. 1Least square means (95% confidence interval) reported for smokers and 
nonsmokers. Quartile means (95% confidence interval) provided for variables associated with CYP1A2 activity (P ≤ 0.15). 2Square root 
transformed. 3Natural log transformed. SE, standard error.Breast Cancer Research    Vol 6 No 4    Hong et al.
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levels, or vice versa, although there is evidence to suggest
that these variables may mutually affect each other. In a
recent randomized study of healthy elderly (≥ 70 years)
men on the effects of administered recombinant human GH
[35], those given GH had increased IGF-1 levels and
increased CMR, as a measure of CYP1A2 activity, com-
pared with those given placebo. There is also some evi-
dence from animal studies that insulin can induce CYP1A2
activity [36], and obese Zucker rats, which exhibit hyperin-
sulinemia, hyperglycemia, and hypercholesterolemia com-
pared with lean Zucker rats, also exhibit higher CYP1A2
levels [37].
In the opposite direction, microarray analysis of CYP1A2-/-
knockout mice suggests a role for CYP1A2 in the expres-
sion of insulin and IGF-1 genes. CYP1A2-/- mice exhibited
downregulation of genes involved in insulin action, includ-
ing IGFBP-1, glucokinase, and phosphenolpyruvate car-
boxykinase-1, which catalyzes the rate-limiting step in
glucogenesis [38]. These changes in gene expression may
be linked to an overall downregulation of cell proliferation,
changes in sex steroid and SHBG production, and/or alter-
ations in lipid metabolism [38].
Increased levels of insulin and/or IGF-1 can potentially
increase breast cancer risk through a number of
mechanisms. Insulin can decrease SHBG levels [39], and
inverse associations were observed in the present study
between SHBG and insulin levels (premenopausal: β = -
0.74 ± 0.37, F = 4.07, P = 0.05; postmenopausal: β = -
0.91 ± 0.32, F = 7.92, P = 0.006) as well as IGF-1 (in post-
menopausal women only: β = -0.22 ± 0.08, F = 8.04, P =
0.005) after adjustment for age, BMI, ethnicity, and WHR.
Insulin can also stimulate adrenocortical aromatase P450
mRNA levels [40]; upregulate steroidogenic acute regula-
tory protein, which increases the rate of cholesterol trans-
port for steroidogenesis [41]; and upregulate transcription
of the gene encoding sterol response-binding protein-1c,
which is involved in the expression of lipogenic genes [38].
In both menopausal groups, CYP1A2 phenotype was not
associated with total estradiol levels, but it was negatively
associated with percentage free estradiol, which in turn is
strongly related to SHBG levels. The positive association
between CYP1A2 activity and SHBG levels (and inverse
associations between CYP1A2 and percentage free estra-
diol) was independent of the relationship of CYP1A2 with
insulin and IGF-1 levels. Because estrogens increase
serum SHBG levels presumably through enhanced hepatic
synthesis [42], lower levels of CYP1A2 activity in the liver
might have a direct effect on enhancing SHBG production
due to an increased level of estrogen activity in the liver,
and this would account for a lowering of plasma free estra-
diol levels.
Inverse associations between CYP1A2 activity and per-
centage free estradiol are consistent with previous reports
that female sex hormones have an inhibitory effect on
CYP1A2 activity. CYP1A2 activity is lower in women [6],
reduced by 35–50% during pregnancy [7], inhibited by
oral contraceptives [6] and hormone replacement therapy
[43], and may be lower during the late luteal phase of the
menstrual cycle, when estradiol concentrations peak [44].
CYP1A2 activity varied negatively with total cholesterol lev-
els in premenopausal women and HDL-cholesterol levels in
postmenopausal women. Relationships between estro-
gens and plasma lipids are well documented, and exoge-
nous estrogens are known to reduce serum lipids and
lipoproteins [45]. Furthermore, 2-hydroxyestrone, a prod-
uct of CYP1A2 activity, has been shown in rats to have a
serum triglyceride reducing effect as strong as that of 17β-
estradiol [46]. Elevated triglyceride levels have been asso-
ciated with increased breast cancer risk in both premeno-
pausal and postmenopausal women [47,48]. In this study,
however, circulating triglyceride levels were positively
associated with CYP1A2 activity in premenopausal
women, and negatively associated in postmenopausal
women. The reason for this is unclear, although findings
were independent of BMI and WHR, which were included
in the analyses as potential predictors of CYP1A2 function.
Findings were not altered when BMI and WHR were forced
into the regression models as potential confounders (data
not shown).
Recent research shows that several genes involved in fatty
acid and cholesterol biosynthetic pathways are downregu-
lated in the CYP1A2 knockout mouse [38]. This may affect
breast cancer risk since steroidogenesis is influenced by
the provision of cholesterol as a substrate [49]. These
findings, however, support a positive association between
CYP1A2 activity and lipid and cholesterol biosynthesis,
whereas our findings generally showed inverse associa-
tions between CYP1A2 activity and circulating cholesterol
and triglyceride levels (in postmenopausal women).
As in previous studies, CYP1A2 function was strongly
induced by tobacco smoke [6,7]. The effect of smoking on
CYP1A2 function may explain why smoking is not an impor-
tant risk factor for breast cancer and may actually be pro-
tective. Cigarette smoking has been observed to increase
2-hydroxylation [50] and reduce the conversion rate of
androgens to estrogens [51]. Brunet and coworkers [52]
recently reported that smoking reduces risk for breast can-
cer by 44% in carriers of BRCA1  or  BRCA2  gene
mutations.
CYP1A2 activity was found to vary inversely with BMI in
premenopausal women after adjusting for other covariates.
These findings were similar to that observed in a study ofAvailable online http://breast-cancer-research.com/content/6/4/R352
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786 Caucasian women [6], which was the first to find an
inverse association between CYP1A2 activity and BMI.
Because increased BMI is associated with reduced risk
before the menopause [53], our findings would suggest
that lower CYP1A2 activity (associated with greater BMI)
in these women would be associated with lower breast
cancer risk. Low 2-hydroxyestrone levels, however, have
been associated with higher risk for breast cancer in pre-
menopausal women [54]. Further study is needed to eluci-
date the relationship between CYP1A2 activity, body size,
and breast cancer risk.
CYP1A2 activity was associated with a number of dietary
factors in premenopausal women but not in postmenopau-
sal women. After adjusting for body size, age, ethnicity, and
smoking status, positive associations were observed with
intake of caffeine, total energy, fat, and protein. After adjust-
ing for other covariates through stepwise and maximum R
regression, however, only caffeine intake remained signifi-
cant. The positive association between caffeine intake and
CYP1A2 activity in premenopausal women is consistent
with results from other studies that suggest that caffeine
can induce CYP1A2 activity [6,7,55]. This has been
observed in population [12] as well as rat studies [56].
Limitations of the present study include the small number of
participants, particularly after stratification by menopausal
status. The research was exploratory in nature, and so novel
findings, such as associations observed with insulin and
IGF-1 levels, as well as with blood lipids and cholesterol,
are more likely due to chance and need replication in future
studies.
Conclusion
Results from the present cross-sectional study suggests
that several factors associated with breast cancer risk are
associated with CYP1A2 activity, including SHBG and free
estradiol levels, insulin and IGF-1, blood lipids and choles-
terol, body size, and smoking status. Some of the observed
associations, however, were contrary to hypothesized
directions and suggest that increased CYP1A2 function
may be associated with increased risk for breast cancer.
These preliminary findings need confirmation in future stud-
ies. The association of risk factors with the activity of meta-
bolic enzymes, particularly those under substantial genetic
control, may suggest important pathways in the develop-
ment of breast cancer. Further research is required to elu-
cidate the relationships between CYP1A2 genotype,
CYP1A2 phenotype, their influence on risk factors
associated with breast cancer, and their impact on breast
cancer risk.
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